Recombinant IFNA2 anticorps (PE)

N° du produit ABIN7867330

Cet anticorps anti-IFNA2 Chimeric Lapin conjugué à PE (Clone 1B7) (ABIN7867330) détecte spécifiquement IFNA2 dans FACS. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour Recombinant IFNA2 anticorps (PE) (ABIN7867330)

Antigène: IFNA2 (Interferon, alpha 2 (IFNA2))

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Lapin

Clonalité: Chimeric

Conjugué: Cet anticorp IFNA2 est conjugé à/à la PE

Application: Flow Cytometry (FACS)

Clone: 1B7

Détail du produit anti-IFNA2 anticorps (PE)

Fonction: PE-conjugated Anti-IFNA2 antibody(1B7), IgG1 Chimeric mAb

Purification: Purified from cell culture supernatant by affinity chromatography

Isotype: IgG1

Information d'application

Indications d'application: Flow Cyt 1:100

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Liquid PBS with 0.05 %  Proclin300, 1 % BSA

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Store at 2°C-8°C for 6 months

Date de péremption: 6 months

Détails sur IFNA2

Antigène: IFNA2 (Interferon, alpha 2 (IFNA2))

Autre désignation: IFNA2

Sujet:

Synonyms: IFNA, IFNA2B, leIF A, IFN-alphaA, IFN-alpha-2

Target Background: This gene is a member of the alpha interferon gene cluster on chromosome 9. The encoded cytokine is a member of the type I interferon family that is produced in response to viral infection as a key part of the innate immune response with potent antiviral, antiproliferative and immunomodulatory properties. This cytokine, like other type I interferons, binds a plasma membrane receptor made of IFNAR1 and IFNAR2 that is ubiquitously expressed, and thus is able to act on virtually all body cells. The encoded protein is effective in reducing the symptoms and duration of the common cold and in treating many types of cancer, including some hematological malignancies and solid tumors. A deficiency of type I interferon in the blood is thought to be a hallmark of severe COVID-19 and may provide a rationale for a combined therapeutic approach. [provided by RefSeq, Aug 2020]

UniProt: P01563

Pathways: Signalistation JAK/STAT, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Hepatitis C